Daria J. Hazuda

What is she best known for?

The fields of study she is best known for:

• Gene
• Enzyme
• DNA

Her main research concerns Virology, Integrase, Virus, Viral replication and Integrase inhibitor. She interconnects Acquired immunodeficiency syndrome and Immunology in the investigation of issues within Virology. Her Integrase study integrates concerns from other disciplines, such as Lentivirus and In vitro, Enzyme inhibitor, Enzyme.

Her work focuses on many connections between Viral replication and other disciplines, such as Molecular biology, that overlap with her field of interest in Jurkat cells and Kinase. The Integrase inhibitor study combines topics in areas such as Raltegravir Potassium and Raltegravir. Her Biochemistry research includes themes of Stereochemistry and Amyloid precursor protein.

Her most cited work include:

• Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells (972 citations)
• Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy (854 citations)
• The challenge of finding a cure for HIV infection. (716 citations)

What are the main themes of her work throughout her whole career to date?

Her primary scientific interests are in Virology, Integrase, Stereochemistry, Enzyme and Virus. Her Virology research is multidisciplinary, incorporating perspectives in Reverse transcriptase and Immunology. Her Integrase research is multidisciplinary, relying on both Integrase inhibitor, In vitro, Viral replication and Lentivirus.

She usually deals with Integrase inhibitor and limits it to topics linked to Raltegravir and Raltegravir Potassium, Elvitegravir and Pharmacology. Her Enzyme study necessitates a more in-depth grasp of Biochemistry. Her biological study deals with issues like Mutant, which deal with fields such as Mutation.

She most often published in these fields:

• Virology (34.11%)
• Integrase (31.01%)
• Stereochemistry (21.32%)

What were the highlights of her more recent work (between 2015-2021)?

• Virology (34.11%)
• Immune system (5.81%)
• Immunology (8.53%)

In recent papers she was focusing on the following fields of study:

Her primary areas of study are Virology, Immune system, Immunology, In vivo and Virus. Her work in the fields of Virology, such as Viral replication and Hepatitis C virus, intersects with other areas such as Population. As a part of the same scientific study, Daria J. Hazuda usually deals with the Immunology, concentrating on Antiretroviral therapy and frequently concerns with Pegylated interferon, Pegylated interferon alpha-2b and Persistently infected.

Her In vivo course of study focuses on Cell and Histone deacetylase. Her research integrates issues of Asymptomatic and Mutant in her study of Virus. Her study looks at the relationship between Mutant and topics such as Nucleoside Reverse Transcriptase Inhibitor, which overlap with Molecular biology.

Between 2015 and 2021, her most popular works were:

• Latency reversal and viral clearance to cure HIV-1 (152 citations)
• PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. (64 citations)
• CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. (63 citations)

In her most recent research, the most cited papers focused on:

• Gene
• Enzyme
• DNA

Daria J. Hazuda mostly deals with Virology, Virus, Immune system, Immunology and Virus latency. Her Virology research is multidisciplinary, incorporating elements of Rilpivirine, Mutant and Dose–response relationship. Her research in Virus intersects with topics in Protein subunit, Epitope, Antigen, Immunogenicity and Vaccination.

Vorinostat, Cell killing and Provirus is closely connected to Viral protein in her research, which is encompassed under the umbrella topic of Immune system. Daria J. Hazuda frequently studies issues relating to Asymptomatic and Immunology. Daria J. Hazuda has researched Virus latency in several fields, including Cell, Ex vivo, Histone deacetylase, Panobinostat and T cell.